Snigdha Sharma, MD
Critical Care Medicine · Conway, SCNPI 1013358712
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,473 of the $4,925 with a category attached, or 70.5%. 21 manufacturers reported payments, led by Johnson & Johnson at 26.7% of the total. Reporting peaked in 2022 at $1,822 and has fallen 53.7% since, to $843 in 2025.
Across 155 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$1K
- GSK$713
- Insmed, Inc.$437
- Regeneron Healthcare Solutions, Inc.$309
- Boehringer Ingelheim$298
- plus $803 from 15 others
What the payments were for
- Travel & lodging$1,20224%
- Food & beverage$3,47371%
- Education$2505%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 10 | $1,316 |
| AstraZeneca | 50 | $1,049 |
| GSK | 36 | $713 |
| Insmed, Inc. | 10 | $437 |
| Regeneron Healthcare Solutions, Inc. | 8 | $309 |
| Boehringer Ingelheim | 13 | $298 |
| Sanofi | 4 | $195 |
| Mylan Specialty L.p. | 5 | $105 |
| Genentech USA, Inc. | 1 | $86 |
| Mallinckrodt Hospital Products Inc. | 3 | $72 |
| Actelion Pharmaceuticals US, Inc. | 2 | $64 |
| Baxter Healthcare | 2 | $46 |
| Philips North America LLC | 2 | $40 |
| Merck | 1 | $33 |
| Advanced Respiratory, Inc | 2 | $30 |
| Astellas Pharma US Inc | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Vapotherm Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,200
- DUPIXENT$346
How this compares
$4,925 in reported general payments places this provider in the 75th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 572 | $497,437 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 149 | $130,680 |
| Spiriva RespimatTiotropium Bromide | 80 | $67,194 |
| NucalaMepolizumab | 15 | $54,812 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $50,136 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 82 | $46,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 941 | $25,725 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $22,892 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $17,820 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $17,571 |
| Spiriva HandihalerTiotropium Bromide | 20 | $13,134 |
| Arnuity ElliptaFluticasone Furoate | 40 | $11,809 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $11,735 |
| Wixela InhubFluticasone Propion/Salmeterol | 60 | $10,668 |
| Ventolin HfaAlbuterol Sulfate | 69 | $3,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $713 | $678,419850 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,049 | $148,251195 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $298 | $90,086124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Conway
- Hafez HayekConway$138K
- Ami VaidyaConway$4K
- Charlton StrangeCharleston$205K
- William AlleyneRock Hill$199K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Nicholas FoxCharleston$88K
- Nasir AwanGreenville$54K
- Christopher GilbertCharleston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.